SMi EVENT – 4th annual Immunogenicity

SMi is thrilled to present the return of its 4th annual Immunogenicity conference and exhibition, taking place in London on the 12th – 13th June 2017.


The immunogenicity market has seen considerable progression over recent years, with innovative developments apparent in predicting and controlling immunogenicity. However the industry is still subject to complex hurdles and challenges.

This year’s conference will provide attendees with a thorough understanding of the continued need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. Speakers will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for all delegates in attendance, Immunogenicity 2017 will identify and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.

At SMi’s 4th annual Immunogenicity conference, industry, regulatory and academic experts will gather to spark debate and progress on the causes of immunogenicity, predicting and preventing its effects, and its associated issues. Immunogenicity 2017 will offer unparalleled networking opportunities, deep insight into industry issues, and spotlight sessions on innovations and emerging technologies for immunogenicity.

Visit the website for further details at or contact at

Journal: Current Immunology Reviews 

EBook: The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis 

Measles Immunisation Day – 16th March 2017!


Measles is a highly contagious viral disease which affects mostly children. It is one of the leading causes of death and disability among young children. Measles Immunisation Day is celebrated on 16th march every year to make people aware about this deadly disease and how they can deal with the same.
Bentham Science publishes research papers that present new studies related to to this particular disease. Find the latest studies in the following journal:

World Leprosy Eradication Day!


Leprosy, also known as Hansen’s disease (HD), is a long-term infection by the bacteria Mycobacterium leprae. Symptoms of leprosy include granulomas of the nerves, respiratory tract, skin, and eyes, which result in lack of ability to feel pain.
Bentham Science publishes research papers that present new studies to help eradicate Leprosy. Find the latest studies in the following journals:

Immunology‚ Endocrine & Metabolic Agents in Medicinal ChemistryInfectious Disorders – Drug TargetsCurrent Immunology Reviews

Testimonial by Dr. Konstantin V. Suslov!

Dr. Konstantin V. Suslov

Dr. Konstantin V. Suslov

Institute of Immunology, 24/2 Kashirskoe Sh.,

Moscow 115 478, Russia

Contributed Article: Orchestrating HIV Neutralization by Secondary Immune Response- Mediated Induction of RF Antibodies

Upcoming Thematic Issue – Heat Shock Proteins in Health and Disease

Hottopic- Cir- Jurgen Radons

E-Pub Ahead of Print :: “Developments Towards a Prophylactic Hepatitis C Virus Vaccine”

Journal: Current Immunology Reviews

Author(s): Brian P. Latimer, Ebony Gary and Michele A Kutzler

cirAbstract: Chronic hepatitis C virus (HCV) infection is a major health problem worldwide, affecting approximately 3% of the human population. Although decades of research have amassed since the virus was characterized in 1989, there remains no prophylactic HCV vaccine approved for clinical use. The vast genetic variability of HCV, together with weak host immune responses following infection, and a paucity of suitable animal models for HCV vaccine research, have made HCV an elusive vaccine target. Despite the recent advances in medical treatment enjoyed by wealthy nations, there remains an unmet need for an affordable, effective, and accessible means to control HCV disease burden in areas of limited resources, where HCV is most problematic. To this end, several promising HCV vaccine candidates have been reported in recent preclinical and clinical trials. Here we review HCV virology and immunology relevant to rational design of a prophylactic HCV vaccine, and recent studies of preclinical and clinical HCV vaccine candidates.

For more details:

Recently published issues in various journals of Bentham Science

Current Biotechnology , 5 Issue 2   

CNS & Neurological Disorders – Drug Targets, 15 Issue 4    

Current Immunology Reviews , 12 Issue 1    

 Current Neurovascular Research , 13 Issue 2    

Medicinal Chemistry, 12 Issue 3      

Current Bioinformatics, 11 Issue 2    

Current Cardiology Reviews, 12 Issue 2      

Current Chromatography, 3 Issue 1     

Current Bioactive Compounds, 12 Issue 1       

Drug Delivery Letters, 5 Issue 3  

Current Pharmaceutical Design, 22 Issue 12     

Current Pharmaceutical Design, 22 Issue 13     

Recent Issues